ANI Pharmaceuticals Inc (ANIP)
61.43
-2.34
(-3.67%)
USD |
NASDAQ |
May 17, 16:00
61.45
+0.02
(+0.03%)
After-Hours: 20:00
ANI Pharmaceuticals Accounts Receivable (Quarterly): 172.42M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 172.42M |
December 31, 2023 | 162.08M |
September 30, 2023 | 178.84M |
June 30, 2023 | 172.92M |
March 31, 2023 | 174.71M |
December 31, 2022 | 165.44M |
September 30, 2022 | 140.43M |
June 30, 2022 | 150.41M |
March 31, 2022 | 131.62M |
December 31, 2021 | 128.53M |
September 30, 2021 | 106.71M |
June 30, 2021 | 92.65M |
March 31, 2021 | 91.88M |
December 31, 2020 | 95.79M |
September 30, 2020 | 83.74M |
June 30, 2020 | 73.16M |
March 31, 2020 | 82.38M |
December 31, 2019 | 72.13M |
September 30, 2019 | 70.70M |
June 30, 2019 | 76.27M |
March 31, 2019 | 67.41M |
December 31, 2018 | 64.84M |
September 30, 2018 | 67.65M |
June 30, 2018 | 56.12M |
March 31, 2018 | 54.80M |
Date | Value |
---|---|
December 31, 2017 | 58.79M |
September 30, 2017 | 62.17M |
June 30, 2017 | 55.51M |
March 31, 2017 | 46.70M |
December 31, 2016 | 45.90M |
September 30, 2016 | 47.48M |
June 30, 2016 | 35.56M |
March 31, 2016 | 22.48M |
December 31, 2015 | 21.93M |
September 30, 2015 | 21.64M |
June 30, 2015 | 18.88M |
March 31, 2015 | 17.37M |
December 31, 2014 | 17.30M |
September 30, 2014 | 14.57M |
June 30, 2014 | 7.794M |
March 31, 2014 | 10.91M |
December 31, 2013 | 12.51M |
September 30, 2013 | 9.515M |
June 30, 2013 | 6.428M |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
70.70M
Minimum
Sep 2019
178.84M
Maximum
Sep 2023
121.14M
Average
117.62M
Median
Accounts Receivable (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 28.44M |
ADMA Biologics Inc | 49.62M |
Annovis Bio Inc | -- |
United Therapeutics Corp | 307.30M |
Allogene Therapeutics Inc | -- |